Impact of anti-PDGFRα antibody surface functionalization on LNC uptake by oligodendrocyte progenitor cells.
(2022) International Journal of Pharmaceutics — Vol. 618, p. 121623 (2022)
Files
1-s20-S0378517322001788-main.pdf
Open Access - Adobe PDF
- 3.33 MB
Details
- Authors
- Abstract
- Impairment of oligodendrocyte progenitor cell (OPC) differentiation into oligodendrocytes and chronic inflammation are key determinants of poor remyelination observed in diseases such as multiple sclerosis. For many pro-myelinating molecules, the therapeutic potential is hindered by poor solubility or limited access to the targeted cells. A promising approach to improve the delivery of those molecules to OPC is to encapsulate them in functionalized Lipid Nanocapsules (LNC). We aimed to develop the first OPC-targeting LNC, by grafting an anti-PDGFRα antibody on the surface of the LNC using several strategies and evaluating the interaction with PDGFRα via ELISA. We found that only site-selective click-chemistry grafting maintained anti-PDGFRα/PDGFRα association, which was confirmed in vitro on primary rat OPC. In conclusion, we demonstrated that it was possible to produce anti-PDGFRα functionalized LNC, we confirmed the antibody's ability to recognize its receptor after grafting and we optimized techniques to characterize antibody functionalized LNC.
- Affiliations
Citations
Labrak, Y., Heurtault, B., Frisch, B., Saulnier, P., Lepeltier, E., Miron, V. E., Muccioli, G., & des Rieux, A. (2022). Impact of anti-PDGFRα antibody surface functionalization on LNC uptake by oligodendrocyte progenitor cells. International Journal of Pharmaceutics, 618, 121623. https://doi.org/10.1016/j.ijpharm.2022.121623 (Original work published 2022)